It has been suggested that protein-protein interaction is important for protein kinase C (PKC) ␣ to activate phospholipase D1 (PLD1). To determine the one or more sites on PKC␣ that are involved in binding to PLD1, fragments containing the regulatory domain, catalytic domain, and C1-C3 domain of PKC␣ were constructed and shown to be functional, but they all failed to bind and activate PLD1 in vivo and in vitro. A C-terminal 23-amino acid (aa) deletion mutant of PKC␣ was also found to be inactive. To define the binding/activation site(s) in the C terminus of PKC␣, 1-to 11-aa deletion mutants were made in this terminus. Deletion of up to 9 aa did not alter the ability of PKC␣ to bind and activate PLDl, whereas a 10-aa deletion was inactive. The residue at position 10 was Phe 663 . Mutations of this residue (F663D and F663A) caused loss of binding, activation, and phosphorylation of PLD1, indicating that Phe 663 is essential for these activities. Time course experiments showed that the activation of PLD1 by PMA was much faster than its phosphorylation, and its activity decreased as phosphorylation increased with time. Staurosporine, a PKC inhibitor, completely inhibited PLD1 phosphorylation in response to 4␤-phorbol 12-myristate 13-acetate PMA and blocked the later decrease in PLD activity. The same results were found with the D481E mutant of PKC␣, which is unable to phosphorylate PLD1. These results indicate that neither the regulatory nor catalytic domains of PKC␣ alone can bind to or activate PLD1 and that a residue in the C terminus of PKC␣ (Phe 663 ) is required for these effects. The initial activation of PLD1 by PMA is highly correlated with the binding of PKC␣. Although PKC␣ can phosphorylate PLD1, this is a relatively slow process and is associated with inactivation of the enzyme.
Phospholipase D (PLD)
1 is a ubiquitous enzyme that hydrolyzes phosphatidylcholine to phosphatidic acid (PA) and choline (1) . PA can be metabolized to diacylglycerol (DAG) by PA phosphohydrolase. PA and DAG are involved in receptor-mediated intracellular signal transduction, secretion, cytoskeletal reorganization, and the respiratory burst (2) . To date two isoforms of mammalian PLD (PLD1 and PLD2) have been cloned. These isoforms share about 50% amino acid similarity, but exhibit quite different regulatory properties (2) . PLD1 has a low basal activity and responds to protein kinase C (PKC) and to members of the Rho and Arf families of small G proteins (3) (4) (5) (6) , whereas PLD2 exhibits a high basal activity and shows little or no response to PKC, Rho, or Arf in vitro (7) (8) (9) . The intracellular localization of PLD1 remains ambiguous. Most reports indicate it is localized in the perinuclear region, including the Golgi apparatus, and some have reported its presence in caveolae (10 -12) .
PKC␣ belongs to the group of conventional PKC isoforms that are regulated by Ca 2ϩ , DAG, and phosphatidylserine. It has a regulatory domain, which includes the pseudosubstrate, the C1 (phorbol, DAG binding) and C2 (calcium, phosphatidylserine binding) domains, a catalytic domain, which includes the C3 (ATP binding) domain, and C4 kinase domain. PKC␣ is mainly located in the cytosol and can translocate to membrane fraction upon stimulation by phorbol esters or certain agonists (13) . PKC␣ is considered to play a major role in PLD1 activation (2) . However, the one or more mechanisms involved in PLD1 activation are still not clear. Some studies have shown that PKC␣ activates PLD1 through a phosphorylation-independent mechanism, because PKC␣ could activate this PLD isoform in vitro without ATP (4, 12, 14) confirming earlier work (15, 16) . Furthermore, treatment of phosphorylated PLD1 with Ser/Thr phosphatase did not affect its activity (17) . Instead of phosphorylation, protein-protein interaction has been considered the main mechanism for PKC␣ to activate PLD1. Association between PLD1 and PKC␣ has been observed in COS-7 cells (18) and in Rat1 fibroblasts (19) . Utilizing proteolytic cleavage of PKC␣ to separate the regulatory and catalytic domains, it was suggested that the regulatory domain of PKC␣ was more important for PLD1 activation in vitro (16) .
However, other groups have provided evidence that phosphorylation of PLD1 is needed for its activation. It was found that PMA-dependent PLD1 activation required ATP in cell-free systems from neutrophils and HL60 granulocytes (20) . However, a possible role for ATP in PIP 2 synthesis was not excluded. PLD1 was also found to be phosphorylated by PKC␣ at multiple sites during activation, and the phosphorylation occurred in caveolin-enriched microdomains within the plasma membrane (21, 22) . Mutation of three of the sites resulted in a partial reduction in the ability of PMA to activate the enzyme in vivo (21) .
In this study, we determined the requirements for PKC␣ activation of PLD1. Different fragments of PKC␣, including the regulatory and catalytic domains and one that encompassed the C1-C3 domains, were constructed to see which domain or domains were required for binding and activation of PLD1. In addition, several C-terminal deletion mutants of PKC␣ were constructed to define the role of the C terminus. These studies indicted that both the regulatory and catalytic domains are required and identified Phe 663 as a crucial residue in the binding and activation of PLD1. Studies of the binding of PKC␣ with PLD1 were performed and indicated a high correlation between binding and activation of the phospholipase. The role of phosphorylation was explored by determining the time courses of PLD1 activation and phosphorylation and the effects of a PKC inhibitor and a PKC␣ mutant deficient in kinase activity. The results indicated that phosphorylation was not required for activation of PLD1 but was associated with inactivation.
EXPERIMENTAL PROCEDURES
Materials-4␤-Phorbol 12-myristate 13-acetate (PMA), staurosporine, bovine serum albumin, Nonidet P-40 (Nonidet P-40), phosphatidylinositol 4,5-bisphosphate (PIP 2 ), and horseradish peroxidaseconjugated secondary antibody were from Sigma. Dipalmitoylphosphatidylcholine (PC), phosphatidylethanolamine, and phosphatidylbutanol (PtdBut) standard were from Avanti Polar Lipids Corp. [methyl- ]myristic acid were from PerkinElmer Life Sciences. Protein G-agarose beads, Dulbecco's modified Eagle's medium (DMEM), penicillin, streptomycin, fetal bovine serum, Tris-glycine SDS-polyacrylamide gels, PcDNA3.1(ϩ), PcDNA3.1(HisA,B,C) vectors, and anti-Xpress monoclonal antibody were from Invitrogen. The transfection reagent FuGENE6 and the protease inhibitor mixture were from Roche Molecular Biochemicals. COS-7 cells were from American Type Culture Collection. Anti-PKC␣ monoclonal antibody was from BD Transduction Laboratories. Anti-PKC␣ (C-terminal) monoclonal antibody was from Upstate Biotechnology. Anti-phosphothreonine polyclonal antibody was from Zymed Laboratories Inc. Plasmid and PCR-product purification kits were from Qiagen. QuikChange mutagenesis kit and Pfu Turbo DNA polymerase were purchased from Stratagene. Anti-rabbit IgG, horseradish peroxidase, ECL reagent, and film were from Amersham Biosciences. All restriction enzymes and T4 DNA ligase were from New England BioLabs. The rat PKC␣ in PTB vector and the regulatory domain (1-311) in PCH3 vector were kindly provided by Dr. Susan Jaken (Eli Lilly).
Plasmid Construction-The rat PLD1 was cloned into PcDNA3.1(His) vector with the N-terminal Xpress tag. The rat PKC␣ and its regulatory domain were subcloned at the EcoRI site into PcDNA3.1(ϩ) vector. Catalytic domain (312-672), C1-C3 (1-468), ⌬23 (1-649), ⌬11 (1-661), ⌬10 (1-662), ⌬9 (1-663), ⌬8 (1-664), ⌬7 (1-665), ⌬6 (1-666), ⌬5 (1-667), and ⌬1 (1-671) were generated by PCR with primers containing the 5Ј and 3Ј EcoRI sites. D481E, F663D, and F663A mutants were generated using the QuikChange site-directed mutagenesis kit from Stratagene. All constructs were sequenced to verify the coding regions and were well expressed in COS-7 cells.
Cell Culture and Transfection-COS-7 cells were maintained in DMEM supplemented with 100 units/ml penicillin, 100 g/ml streptomycin, and 10% fetal bovine serum in 10% CO 2 . Six-well plates were seeded with 2 ϫ 10 5 cells/well, and 10-cm dishes were seeded with 8 ϫ 10 5 cells 24 h before transfection with FuGENE6 according to the manufacturer's instructions.
In Vivo PLD Assay-After 5 h of transfection, cells in six-well plates were serum-starved overnight (0.5% fetal bovine serum in DMEM) in the presence of 1 Ci/ml [ 3 H]myristic acid. PLD activity was assayed by incubating the cells with 0.3% 1-butanol for 20 min and measuring the formation of [ 3 H]PtdBut as a percentage of total labeled lipids as described before (23) .
Subcellular Fractionation-After transfection and starvation overnight, 10-cm dishes of COS-7 cells were washed once with ice-cold phosphate-buffered saline and then harvested using lysis buffer (25 mM Hepes, pH 7.2, 10% glycerol, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol, and protease inhibitor mixture). After 10-s sonication for two times, the cell lysate was first centrifuged at 500 ϫ g for 10 min to remove unbroken cells. The supernatant was then spun at 120,000 ϫ g for 45 min at 4°C to separate the cytosolic and crude membrane fractions.
In Vitro PLD Assay-For in vitro assay, the cells were either untransfected or separately transfected with PLD1 or PKC␣ or its mutants. The control supernatant or that containing overexpressed PKC␣ or its mutants was used as the PKC fraction, and the crude membranes containing PLD1 were resuspended in lysis buffer and used as the PLD1 fraction. The PLD1 activity was measured by the formation of [ 3 H]PtdBut in vitro as described previously (14) . Briefly, phospholipid vesicles generated from phosphatidylethanolamine/PIP 2 /PC (16:1.4:1, v/v) containing [palmitoyl-
3 H]PC (0.5 Ci/reaction) were used with 1-butanol (0.6%) as substrate. The reaction mixtures were incubated at 37°C for 30 min and stopped with chloroform/methanol/HCl (50:98:2, v/v). The lipids were extracted from the organic phase and resolved by thin-layer chromatography. Bands co-migrating with a PtdBut standard were quantitated by liquid scintillation counting.
Immunoprecipitation and Western Blotting-COS-7 cells cultured in 10-cm plates were transfected and starved overnight as described above. The cells were washed once with ice-cold phosphate-buffered saline and harvested using immunoprecipitation (IP) buffer containing 25 mM Hepes pH 7.2, 10% glycerol, 1 mM EDTA, 1 mM EGTA, 50 mM KCl, 10 mM NaF, 10 mM Na 4 P 2 O 7 , 1.2 mM Na 3 VO 4 , 1% Nonidet P-40 and protease inhibitors mixture. The cell suspensions were sonicated for 10 s and then spun at 120,000 ϫ g for 45 min to pellet the detergentinsoluble fraction. The supernatant was then precleared by mixing it with 1 g of affinity purified mouse IgG and 20 l of a 1:1 slurry of protein G beads for 1h at 4°C. The mixture was then spun and the supernatant was incubated with 2 l of anti X-press antibody and 20 l of protein G beads overnight. The immunoprecipitates were washed four times with the immunoprecipitation buffer and then resuspended in SDS sample buffer. The samples were analyzed by SDS-PAGE and transferred to polyvinylidene difluoride membranes (Immobilon-P, Millipore). The blots were then blocked with 1% bovine serum albumin and incubated with primary antibody and then with horseradish peroxidase-conjugated secondary antibody. The bands were detected using ECL.
RESULTS

Regulatory, Catalytic, and C1-C3 Domains and a C-terminal Deletion Mutant of PKC␣ Fail to Stimulate PLD1-To see if
some PKC␣ domains might be enough to activate PLD1, the regulatory domain (RD, 1-311, 37 kDa) catalytic domain (CATA, 312-672, 43 kDa), C1-C3 domain (1-468, 55 kDa), and a C-terminal 23-aa deletion mutant (⌬23, 1-649, 76 kDa) were constructed, and their expression, binding, and activation of PLD1 are shown in Fig. 1 . Fig. 1A shows that none of the PKC␣ domains activated the endogenous PLD activity of COS-7 cells in the absence or presence of PMA. Co-expression of the regulatory and catalytic domains also did not restore the stimulation of PLD activity (data not shown). Similar results were obtained with overexpressed PLD1 in COS-7 cells (data not shown). Western blotting (Fig. 1B) shows that all the domains were well expressed and of the appropriate molecular mass. Some additional immunoreactive proteins were present in all samples, corresponding to endogenous PKC␣ and an unknown protein of 46 kDa. The catalytic domain was also well expressed (Fig. 1B) . To demonstrate that the domains were functionally intact, PMA-induced membrane translocation of the wild type enzyme, regulatory domain, and C1-C3 fragment was tested. Fig. 1C shows that all these proteins were translocated. As expected, the catalytic domain did not (data not shown). To test the functional intactness of the catalytic domain, the ability of this fragment and wild type PKC␣ to increase the Thr phosphorylation of proteins in COS-7 cell lysates was examined. Fig. 1D illustrates that both PKC␣ and its catalytic domain induced marked phosphorylation of several proteins.
In vitro PLD1 assay results (Fig. 1E) were consistent with the in vivo PLD results, i.e. none of the PKC␣ domains activated PLD1. Fig. 1 (F and G) shows the results of binding tests between PLD1 and PKC␣ or its domains. Before PMA stimulation, there was slight binding between PLD1 and PKC␣, which was greatly increased by PMA. However, none of the domains was able to bind to PLD1 in the presence or absence of PMA. As shown in Fig. 1B , all the domains were well expressed, as was PLD1 (not shown). Fig. 1 demonstrated that a C-terminal 23-aa deletion of PKC␣ resulted in a loss of its ability to bind and activate PLD1. To further define the residue(s) involved, C-terminal deletion mutants of 1, 5, 6, 7, 8, 9, 10, and 11 aa were made and shown to be well expressed in
Definition of the C-terminal Residues of PKC␣ Required for Activation and Binding of PLD1-
FIG. 1. The effects of PKC␣ domains on binding and activation of PLD1 in COS-7 cells.
A, COS-7 cells were transfected with vector, PKC␣ wild type (WT), RD, CATA, C1-C3, and ⌬23, respectively, and in vivo PLD assay was carried out. B, cells were lysed using lysis buffer containing antiproteases EDTA and EGTA to limit protein degradation. The cell lysates were analyzed by SDS-PAGE on 4 -20% gels and Western blotted using anti-PKC␣ N-terminal antibody for WT, RD, C1-C3, and ⌬23 and anti-PKC␣ C-terminal antibody for CATA, respectively. C, COS-7 cells expressing WT, RD, C1-C3, and ⌬23 PKC␣ were fractionated into membranes and cytosol, respectively, as described under "Experimental Procedures." Each fraction was analyzed by SDS-PAGE and Western blotted using anti-PKC␣ antibody to test the translocation. C, cytosol; M, membranes. D, COS-7 cells expressing WT, CATA, ⌬9, ⌬10, F663D, and F663A PKC␣ were stimulated with PMA and lysed for Western blot analysis using anti-phospho-Thr antibody. Vector-transfected cells stimulated with PMA were used as control. E, COS-7 cells, respectively, expressing PLD1 and WT, RD, CATA, C1-C3, or ⌬23 PKC␣ were fractionated into membrane and cytosolic fractions for in vitro PLD assay. Membranes from PLD1-transfected cells and cytosol from nontransfected cells were used as control. F and G, PLD1 was co-expressed in COS-7 cells COS-7 cells (data not shown). Fig. 2A shows the effects of the different PKC mutants on endogenous PLD activity in vivo. It is evident that, with deletion of 9 C-terminal residues (⌬9), PKC␣ still retained its ability to activate PLD. However, a 10-aa deletion (⌬10) caused PKC␣ to lose this. Similar results were found with overexpressed PLD1 in COS-7 cells (data not
vivo data in that ⌬9 mutant retained the ability to activate PLD1, whereas ⌬10 mutant lost it (Fig. 2B) . Adding higher concentrations of PKC␣ and the ⌬9 mutant increased the PLD activity whereas higher concentrations of the ⌬10 mutant did not, further supporting the conclusion that the ⌬10 mutant is inactive on PLD1 (data not shown). Fig. 2C shows the binding between PLD1 and PKC␣ or its C-terminal 9-and 10-aa deletion mutants. The ⌬9 mutant showed binding with PLD1 in the presence of PMA stimulation that was equivalent to that of the intact enzyme, whereas the ⌬10 mutant showed negligible binding. Importantly, both the ⌬9 and ⌬10 mutants still retained kinase activity as shown by the phosphorylation of proteins in the cell lysates (Fig. 1D) .
Mutation of Phe 663 Causes PKC␣ to Lose Its Ability to Activate and Bind PLD1-The above results indicate that Phe 663 , which is 10 aa from the C terminus, is very important for PKC␣ to activate PLD1. To prove this, two single-amino acid mutants (F663D and F663A) were made to test their effects on PLD1. Both mutants were expressed very well in COS-7 cells and translocated from the cytosol to membrane fraction after PMA stimulation (data not shown). In vivo PLD assays showed that both mutants could not activate endogenous PLD activity in COS-7 cells in the presence or absence of PMA (Fig. 3A) . Similar results were obtained when overexpressed PLD1 in vivo (data not shown). In vitro PLD assay results also showed that both mutants lost the ability to activate PLD1 (Fig. 3B) . Similar results were obtained with higher concentrations of the PKC␣ mutants were employed (data not shown). Fig. 3C shows the binding between PLD1 and the two mutants. The results show that both mutants bound negligibly to PLD1 even in the presence of PMA stimulation. The phosphorylation of PLD1 by PKC␣ was also studied using antibodies to phospho-Ser, phospho-Thr, and phospho-Tyr, and the results showed that only Thr residues were detectably phosphorylated after PMA stimulation (data not shown). Fig. 3D shows the results of PLD1 phosphorylation by PKC␣ and its mutants. The data show that PKC␣ greatly increased PLD1 phosphorylation upon PMA stimulation. The ⌬9 mutant could still phosphorylate PLD1 upon PMA stimulation, whereas the ⌬10 mutant completely lost this function. The two Phe 663 mutants also showed greatly decreased ability to phosphorylate PLD1. Expression of higher levels of the PKC␣ mutants still showed greatly impaired PLD1 phosphorylation (data not shown). As expected from the findings with the deletion mutants, both the F663D and F663A mutants retained general phosphorylating ability (Fig. 1D) . These results indicate that PLD1 is phosphorylated by PKC␣ upon PMA stimulation and indicate that binding is required for this phosphorylation.
Time Course of PLD1 Activity and Thr Phosphorylation after PMA Stimulation-The above results indicated that binding was required for PKC␣ to activate PLD1, because all the deletions and mutations that caused PKC␣ to lose its ability to bind to PLD1 also caused a loss of activation. However, because phosphorylation of PLD1 by PKC␣ must involve some association between the two enzymes, it was ambiguous whether or not PLD1 phosphorylation was required for its activation. To further study the role of phosphorylation in PLD1 activation, the time courses of PLD1 activation and phosphorylation upon PMA stimulation were studied. This required a modification of with WT or RD, CATA, C1-C3, and ⌬23, respectively. Cell lysates were immunoprecipitated using anti-Xpress antibody. Western blotting was carried out using both anti-Xpress and anti-PKC␣ N-terminal antibodies for WT, RD, C1-C3, and ⌬23 (F), or both anti-Xpress and anti-PKC␣ C-terminal antibodies for WT and CATA (G), respectively. Data are representative of at least three separate experiments.
FIG. 2. The effects of PKC␣ C-terminal truncation mutants on binding and activation of PLD1 in COS-7 cells.
A, COS-7 cells were transfected with vector, PKC␣ (WT), or ⌬1, 5, 6, 7, 8, 9, 10, or 11 C-terminal aa mutants, respectively, for in vivo PLD assay. B, membranes from PLD1-transfected cells and cytosol from cells transfected with WT, ⌬9, or ⌬10 PKC␣ were obtained for in vitro assay. Cytosol from nontransfected cells was used as control. C, PLD1 was co-expressed in COS-7 cells with PKC␣ or its ⌬9 and ⌬10 mutants, respectively. Cell lysates were immunoprecipitated using anti-Xpress antibody and Western blotted using both anti-Xpress and anti-PKC␣ antibodies. Data are representative of at least three separate experiments.
the usual protocol, i.e. COS-7 cells were first treated with PMA for 1, 5, 15, 30, and 60 min, then 1-butanol was added, and the cells were incubated for another 2 min. The results are shown in Fig. 4 . It is evident that PLD1 activity rose very rapidly after PMA stimulation, reaching a maximum in about 3-5 min. Thereafter the activity decreased to near basal (0.1% PtdBut) in 30 min. Fig. 4B shows that PKC␣ rapidly translocated from the cytosol to membrane fraction within 1 min upon PMA stimulation and its membrane association increased over 30 -60 min. Fig. 4C shows the time course of PKC␣ binding with PLD1 after PMA treatment. The binding was also detectable at 1 min and increased during the 1-h experiment. Fig. 4D shows that the PLD1 phosphorylation was not evident until 5 min but then continuously increased during the 1-h incubation. The time course results indicated that the activation of PLD1 by PMA was much faster than its phosphorylation. This suggested that PLD1 activation was independent of its phosphorylation and raised the possibility that phosphorylation actually decreased the activity of the phospholipase.
The PKC Inhibitor Staurosporine and a Kinase-deficient PKC␣ Mutant (D481E) Both Eliminate PLD1 Phosphorylation by PMA While Blocking the Later Decline in Activity-To see if phosphorylation of PLD1 does decrease its activity, two kinds of approaches were used: a PKC kinase inhibitor staurosporine and a kinase-deficient PKC␣ mutant (D481E) (24) . Fig. 5A shows that staurosporine strongly inhibited PLD1 phosphorylation induced by PKC␣ in the presence of PMA. The D481E mutant also showed barely detectable phosphorylation of PLD1 upon PMA stimulation (Fig. 5B) , consistent with its lack of kinase activity. The time course experiments (Fig. 5C) showed that the inhibitor partially blocked the peak activation of PLD1 induced by PMA (0 -10 min) and diminished the later decline in activity (10 -30 min) . Similar results were seen in cells expressing endogenous PKC (data not shown). Compared with wild type PKC␣, in cells expressing the D481E mutant, PMA induced a smaller initial activation of PLD and a slower later decline in PLD activity (Fig. 5C) . In an effort to explain the differences in peak PLD activity, the effects of staurosporine and the D481E mutation on the binding of PKC␣ to PLD1 were tested. Staurosporine caused a minimal effect on the binding between PKC␣ and PLD1 in the absence of PMA but partially reduced the association in the presence of the phorbol ester (Fig. 5D ). Binding to PLD1 was also less with the D481E mutant compared with wild type PKC␣ (Fig. 5E ).
DISCUSSION
Binding between PKC␣ and PLD1 was first observed in COS-7 cells (17) and later in Swiss 3T3 fibroblasts (18) . However, these studies did not examine the relationship between the binding and the activation of PLD1. In the present study, we provide much evidence that the activation of PLD1 by PMA is highly correlated with the binding of PKC␣. This was demonstrated by the effects of deletions and mutations in PKC␣ on the two parameters (Figs. 2-4) and was supported by the observation that the initial time course of activation of PLD1 was correlated with its association with PKC␣ and not with its phosphorylation.
A major binding site for PKC␣ on PLD1 is located at the N terminus (25) (26) (27) , and it is likely that there is an additional site (26) . However, the binding sites on PKC␣ for PLD1 are still not defined. In this study, we initially focused on the binding sites for PLD1 in PKC␣. A previous report using proteolysis and chromatography to separate the regulatory and catalytic domains of PKC␣ indicated that the regulatory domain might be the critical region for PLD1 activation in vitro (16) , 2 so we first studied the binding between PLD1 and this domain and showed no detectable binding. More PKC␣ fragments were made, including the catalytic domain and the C1-C3 fragment, but these fragments also failed to bind and activate PLD1. The fragments were shown to be functionally intact by either their membrane translocation in response to PMA or their retention of kinase activity. Thus these data indicated that PKC␣ with both the regulatory and catalytic domains intact was required for association and activation of PLD1.
Because PLD is membrane-associated, it is likely that the interaction between PKC␣ and PLD1 occurs at a membrane locus. Thus the C1 and C2 domains of the regulatory domain, which are required for membrane targeting and translocation of PKC␣ (29 -31) would seem to be essential for activation of PLD1. By this reasoning, the catalytic domain, which stays in the cytosol irrespective of PMA stimulation (data not shown), should be unable to activate PLD1. The observation that the ⌬23 mutant, which possesses the domains for membrane targeting, was unable to activate PLD1, indicates that PKC␣ also requires one or more residues in the C terminus to bind and activate PLD1.
Previous reports showed that, with deletion of up to 11 aa in the C terminus, PKC␣ retained kinase activity (32), so we made more C-terminal truncation mutants to study their effects on PLD1 activity. The results showed that the ⌬9 mutant still bound to and activated PLD1, whereas the ⌬10 mutant did not, and that both mutants retained kinase activity. In support of the conclusion that the C-terminal 10-aa position (Phe 663 ) is important for PKC␣ to activate PLD1, two mutants of this residue (F663D and F663A) also failed to bind and activate PLD1. In agreement with a previous study (32) , the F663D, F663A, and ⌬10 mutants retained kinase activity (Fig. 1D) . Thus the inability of these mutants to phosphorylate PLD1 (Fig. 3D) reflects their inability to bind to the phospholipase (Figs. 2C and 3C) .
The issue of whether or not phosphorylation is needed for PLD1 activation remains controversial. Several studies have shown that ATP is not needed for PKC␣ to activate PLD in vitro (4, 12, 14 -16) . Also, Ser/Thr phosphatase treatment dephosphorylates PLD1 in vitro but does not inhibit its activity (17) . However, there is also a report showing that PLD1 is phosphorylated during activation by PKC␣ (22) . Trypsin treatment of the phosphorylated enzyme immunoprecipitated from cells treated with PMA, followed by two-dimensional peptide mapping, revealed multiple P-peptides (22) . Some of these overlapped with P-peptides generated from the phosphorylation of PLD1 by PKC␣ in vitro. These P-peptides were analyzed by mass spectrometry to reveal phosphorylation of PLD1 at residues Ser 2 , Thr 147 , and Ser 561 (22) . Mutation of these to Ala resulted in a partial loss of PMA-stimulated PLD activity in vivo. However, many other P-peptides were not analyzed, raising the question of what phosphorylation of these other residues would do to PLD1 activity. In addition, the effects of the mutations on the activation of PLD1 by PKC␣ in vitro were not tested.
Our results showed that PLD1 becomes Thr-phosphorylated during PMA treatment of cells expressing wild type PKC␣ but not the ⌬10, F663D, and F663A mutants (Fig. 3D) . However, to answer the key question of whether or not this phosphorylation is required for PLD1 activation, we carried out time course experiments to measure the real-time PLD1 activity after PMA treatment (Fig. 4A) (32) . Once PtdBut is formed in the PLD assay, it is only slowly degraded, so that the standard assay, in which 1-butanol is added first and then PMA is added for different time lengths, only reflects the accumulation of Ptd- But, not the real-time PLD1 activity. The real-time results indicated that the increase in PLD1 activity was much faster than the phosphorylation increase (Fig. 4, compare A with D) . After the initial peak of PLD1 activation, there was a slower decrease in activity, consistent with the frequently observed phenomenon that PtdBut accumulation ceases after several minutes of treatment with PMA or some agonists when PLD activity is measured using the conventional assay (see Ref. 33 , and references therein). Thus, the initial activity increase was not associated with detectable phosphorylation, whereas the subsequent activity decrease was correlated with increased phosphorylation (Fig. 4, A and D) . In other words, the results were consistent with PLD1 phosphorylation having an inhibitory effect on activity. PLD1 activity quickly reached its peak at 1 min, and membrane translocation and association of PKC␣ with PLD1 could be detected at that time (Fig. 4, A-C) . It therefore appears that the initial association of PKC␣ with PLD1 is sufficient for PLD1 to reach its full activation.
To further explore the relationship between PLD1 activation and phosphorylation, a PKC kinase inhibitor staurosporine and a kinase-deficient PKC␣ mutant (D481E) were used. As expected, staurosporine strongly inhibited PLD1 phosphorylation upon PMA stimulation (Fig. 5A) . The D481E mutant also caused negligible phosphorylation of the enzyme (Fig. 5B ) consistent with its lack of kinase activity. When the effects of these agents on the PLD1 activity time course in response to PMA were compared with wild type PKC␣ alone, both the inhibitor and the D481E mutation induced a lower peak of PLD1 activity, but then slowed the subsequent decline in activity (Fig.   5C ). The latter results support the conclusion that phosphorylation of PLD1 inhibits its activity. However, the effects of both staurosporine and D481E on the PLD1 peak activity were not consistent with our proposed effect of phosphorylation. To study this, we explored the effects of these agents on the association between PLD1 and PKC␣. Fig. 5D shows that staurosporine partly decreased the association in the presence of PMA, and Fig. 5E shows that the D481E mutant bound PLD1 to a less extent than wild type PKC␣. These changes in the association with PLD1 could explain the reduced initial activation of PLD. The reasons are unclear why staurosporine and the D481E mutation partly reduce the association of PKC␣ with PLD1 and, hence, decrease the initial activation of PLD1. This is because the domains in PKC␣ that are involved in the binding/activation of PLD1 are unknown. Presumably the D481E mutation partially disrupts this interaction, as does the binding of staurosporine to the catalytic (ATP binding) domain.
In summary, our results indicate that both the regulatory and catalytic domains of PKC␣ are required for activation of PLD1 and that there is a required residue (Phe 663 ) in the C terminus. Surprisingly, our data indicate that phosphorylation is not required for the stimulatory action of PKC␣ on the enzyme in vivo and suggest that phosphorylation is involved in the down-regulation of PLD activation that is commonly seen at later times in cells treated with PMA and agonists.
Acknowledgment-We thank Judy Nixon for help in the preparation of the manuscript. Cell lysates were immunoprecipitated using anti-Xpress antibody and Western blotted using anti-Phospho-Thr antibody (PThrPLD). Cells with no SP treatment were used as control. B, PLD1 was co-expressed in COS-7 cells with WT or D481E PKC␣. After 30-min treatment with PMA (100 nM) cell lysates were immunoprecipitated using anti-Xpress antibody and Western blotted using anti-Phospho-Thr antibody. C, cells were co-transfected with PLD1 and WT PKC␣ (for control and SP time course) or D481E PKC␣ (for D481E time course). Cells were treated with PMA for 1, 5, 15, and 30 min (for SP time course, 100 nM SP was added 30 min before PMA stimulation). 1-Butanol was then added, and incubation was continued for additional 2 min. 1-Butanol was also added to cells without PMA treatment for 2 min as 0-min control. Control, SP, and D481E time courses are shown as diamonds, squares, and triangles, respectively. D, cells were co-transfected with PLD1 and PKC␣ and treated with SP (20 and 100 nM) for 30 min before 30-min treatment with PMA (100 nM). Cell lysates were immunoprecipitated using anti-Xpress antibody and Western blotted using both anti-Xpress and anti-PKC␣ antibodies. E, cells were co-transfected with PLD1 and D481E and treated with PMA (100 nM) for 30 min. Cell lysates were immunoprecipitated with anti-Xpress antibody and Western blotted with anti-PKC␣ antibody. Data are representative of at least three separate experiments.
